Itch reduction was evaluated as a key secondary endpoint in randomized, double-blind, placebo-controlled trials: 3 adult trials, 1 trial in adolescents (12-17 years of age), 1 trial in children (6-11 years of age), and 1 trial in infants to preschoolers (6 months to 5 years of age).1 Click here for additional clinical trial design information.
Itch reduction with DUPIXENT was rapid and sustained in adults at 52 weeks. In SOLO 1, a significantly greater proportion of adult patients had improvement on the Peak Pruritus NRS score vs placebo (defined as at least a 4-point improvement) as early as Week 2 (9% of DUPIXENT patients achieved ≥4-point reduction in NRS score at Week 2 vs 3% with placebo [P=0.0097]).1,2
In addition, in CHRONOS1,4:
A greater proportion of adolescents treated with DUPIXENT and children treated with DUPIXENT + TCS achieved an improvement in the Peak Pruritus NRS compared with placebo (defined as ≥4-point improvement) and as early as Week 4 in adolescents (22% with DUPIXENT vs 5% with placebo; nominal P<0.001).5
A greater proportion of infants to preschoolers treated with DUPIXENT + TCS had an improvement in Worst Scratch/Itch NRS compared with placebo (defined as ≥4-point improvement) at Week 3 (48% with DUPIXENT + TCS vs 9% with placebo + TCS).1,2
Review Adult Peak Pruritus NRS
Results
Review Adolescent Peak
Pruritus NRS Results
Review the Peak Pruritus NRS
Results in Children
Review the Worst Scratch/
Itch NRS Results in Infants to
Preschoolers